北京索萊寶科技有限公司
專注于生物學(xué)試劑及試劑盒領(lǐng)域
服務(wù)熱線：18101056239
專注于生物學(xué)試劑及試劑盒領(lǐng)域
服務(wù)熱線：18101056239
更新時(shí)間：2025-05-19
點(diǎn)擊次數(shù)：1065
1、簡(jiǎn)介
干擾素（IFN）多效性細(xì)胞因子家族，根據(jù)受體特異性可分為三型：I型（含IFN-α/β等13個(gè)亞型，通過(guò)IFNAR1/IFNAR2受體傳遞信號(hào)）、II型（僅包含IFN-γ，特異性結(jié)合IFNGR1/IFNGR2受體）及III型（IFN-λ，依賴IL-10R2/IFNLR1受體發(fā)揮作用）[1-2]。IFN-γ是Ⅱ型干擾素的成員，其基因定位于人類染色體12q15區(qū)域，包含4個(gè)外顯子，其編碼基因在脊椎動(dòng)物中呈現(xiàn)高度保守性（人鼠氨基酸序列同源性約70%）。編碼的成熟蛋白由143個(gè)氨基酸通過(guò)鏈間二硫鍵形成功能性同源二聚體，其受體結(jié)合域中保守的α螺旋結(jié)構(gòu)對(duì)生物活性至關(guān)重要[3]。
IFN-γ主要由T淋巴細(xì)胞、自然殺傷細(xì)胞（NK）和抗原提呈細(xì)胞（APCs，包括單核細(xì)胞、巨噬細(xì)胞和樹突狀細(xì)胞）分泌[4-6]。其表達(dá)受先天免疫信號(hào)的嚴(yán)格調(diào)控，APCs通過(guò)分泌IL-12/IL-18激活STAT4/NF-κB通路，一方面趨化NK細(xì)胞向炎癥部位遷移，另一方面直接誘導(dǎo)IFN-γ基因轉(zhuǎn)錄，形成連接病原識(shí)別與適應(yīng)性免疫啟動(dòng)的關(guān)鍵調(diào)控軸[7-9]。
作為免疫微環(huán)境的核心調(diào)控者，IFN-γ在感染部位呈現(xiàn)爆發(fā)式表達(dá)特征，其通過(guò)激活巨噬細(xì)胞殺菌功能、上調(diào)MHC分子表達(dá)及驅(qū)動(dòng)Th1分化等機(jī)制增強(qiáng)宿主防御[10]。同時(shí)，該因子在腫瘤免疫中發(fā)揮雙重作用：既可誘導(dǎo)腫瘤細(xì)胞免疫原性死亡，又能促進(jìn)免疫檢查點(diǎn)分子（如PD-L1）表達(dá)形成負(fù)反饋調(diào)控[11]。這種功能復(fù)雜性與其特殊的信號(hào)級(jí)聯(lián)機(jī)制直接相關(guān)，IFN-γ通過(guò)結(jié)合異源二聚體受體（IFNGR1/IFNGR2），觸發(fā)JAK1/JAK2-STAT1磷酸化級(jí)聯(lián)反應(yīng)，磷酸化STAT1入核后協(xié)同IRF家族蛋白，通過(guò)結(jié)合干擾素刺激反應(yīng)元件（ISRE）啟動(dòng)數(shù)百種干擾素刺激基因（ISGs）轉(zhuǎn)錄，形成級(jí)聯(lián)放大效應(yīng)。
2、功能或作用機(jī)制
1）受體激活與激酶級(jí)聯(lián)
IFN-γ以同源二聚體形式結(jié)合異源二聚體受體IFNGR，誘導(dǎo)受體構(gòu)象變化。此過(guò)程激活受體偶聯(lián)的JAK1（結(jié)合IFNGR2）和JAK2（結(jié)合IFNGR1）酪氨酸激酶，觸發(fā)二者相互磷酸化?；罨腏AK1進(jìn)一步磷酸化IFNGR1鏈第440位酪氨酸殘基（Y440），形成兩個(gè)相鄰的STAT1蛋白SH2結(jié)構(gòu)域結(jié)合位點(diǎn)[12-14]。
2）STAT1磷酸化與復(fù)合物組裝
募集至受體的STAT1分子在其C端Y701位點(diǎn)被JAK激酶磷酸化，激活誘導(dǎo)STAT1同源二聚化并從受體解離，同源二聚體進(jìn)一步激活激活I(lǐng)RF-1（Interferon Regulatory Factor-1，干擾素調(diào)節(jié)因子-1）及IFN-γ激活序列（GAS），以啟動(dòng)后續(xù)的基因轉(zhuǎn)錄調(diào)控，而少部分受體解離的STAT1會(huì)與STAT2及IRF-9形成異源復(fù)合物[15-17]。其中，STAT1:STAT1:IRF-9復(fù)合物調(diào)控經(jīng)典GAS（IFN-γ-激活序列）響應(yīng)基因；STAT1:STAT2:IRF-9（ISGF3復(fù)合物）：靶向ISRE（干擾素刺激反應(yīng)元件）
3）核轉(zhuǎn)位與基因轉(zhuǎn)錄調(diào)控
磷酸化Stat1同源二聚體與ISGF3復(fù)合物轉(zhuǎn)位入核，分別結(jié)合靶基因啟動(dòng)子區(qū)的GAS和ISRE元件[18]。IRF-1作為次級(jí)轉(zhuǎn)錄因子，進(jìn)一步擴(kuò)大調(diào)控網(wǎng)絡(luò)。此過(guò)程激活包括ICAM-1（細(xì)胞間黏附分子）、iNOS（誘導(dǎo)型一氧化氮合酶）及IRF家族成員在內(nèi)的多種干擾素調(diào)控基因，形成多層級(jí)轉(zhuǎn)錄放大效應(yīng)。
3、臨床應(yīng)用
1）抗感染
IFN-γ作為一種重要的免疫調(diào)節(jié)因子，在抗感染過(guò)程中發(fā)揮著關(guān)鍵作用。它通過(guò)激活巨噬細(xì)胞，增強(qiáng)其吞噬和殺傷能力，促進(jìn)抗原提呈，從而提高機(jī)體對(duì)病原體的清除效率[20]。此外，IFN-γ還能誘導(dǎo)產(chǎn)生抗菌肽和其他具有直接殺菌作用的分子，進(jìn)一步加強(qiáng)宿主防御功能。
2）抗腫瘤
IFN-γ在腫瘤免疫監(jiān)視中占據(jù)核心地位，能夠直接抑制腫瘤細(xì)胞增殖，并通過(guò)多種途徑增強(qiáng)機(jī)體的抗腫瘤免疫反應(yīng)。IFN-γ可以上調(diào)MHC I類分子表達(dá)，使腫瘤細(xì)胞更容易被識(shí)別；刺激NK細(xì)胞、T細(xì)胞等效應(yīng)細(xì)胞的活性；誘導(dǎo)免疫檢查點(diǎn)分子如PD-L1的表達(dá)，進(jìn)而調(diào)節(jié)腫瘤微環(huán)境中的免疫平衡[11,21-22]。
3）自身免疫性疾病
過(guò)度活躍的IFN-γ信號(hào)可能導(dǎo)致自身免疫性疾病的發(fā)生和發(fā)展，如系統(tǒng)性紅斑狼瘡（SLE）、多發(fā)性硬化癥（MS）等[23-24]。針對(duì)IFN-γ信號(hào)通路的關(guān)鍵節(jié)點(diǎn)進(jìn)行干預(yù)，如使用單克隆抗體阻斷IFN-γ與其受體結(jié)合，或設(shè)計(jì)小分子化合物抑制下游信號(hào)傳導(dǎo)，可有效控制病情進(jìn)展，減少并發(fā)癥。
4）移植排斥反應(yīng)
術(shù)后，供體與受體之間的HLA（Human Leukocyte Antigen，人類白細(xì)胞抗原）差異是引發(fā)急性排斥反應(yīng)的主要原因。IFN-γ在此過(guò)程中扮演重要角色，它能增強(qiáng)移植物特異性T細(xì)胞的活化，加劇局部炎癥反應(yīng)，最終導(dǎo)致移植物功能喪失。IFN-γ抑制藥物可下調(diào)移植排斥介導(dǎo)的免疫應(yīng)答。此外，IL-10等具有抗炎效果的細(xì)胞因子，可以作為潛在的治療策略，減輕IFN-γ帶來(lái)的不利影響[25]。
5）神經(jīng)退行性疾病
IFN-γ在神經(jīng)退行性疾病如阿爾茨海默?。ˋD）、帕金森病（PD）中顯示出復(fù)雜的雙重作用。一方面，適度的IFN-γ水平有助于清除β-淀粉樣蛋白沉積物，減緩疾病進(jìn)程；另一方面，過(guò)量的IFN-γ可能會(huì)加重神經(jīng)炎癥，損害神經(jīng)元結(jié)構(gòu)與功能[26]。針對(duì)IFN-γ在神經(jīng)退行性疾病中的復(fù)雜角色，未來(lái)的研究需要更加細(xì)致地解析其調(diào)控網(wǎng)絡(luò)，以期找到既能利用其有益效應(yīng)又能避免不良后果的治療方案。
相關(guān)產(chǎn)品
參考文獻(xiàn)
[1] Bazan, J. F. (1990) Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA 87, 6934– 6938.
[2] Thoreau, E., Petridou, B., Kelly, P. A., Djiane, J., Mornon, J. P. (1991) Structural symmetry of the extracellular domain of the cytokine/growth hormone/prolactin receptor family and interferon receptors revealed by hydrophobic cluster analysis. FEBS Lett. 282, 26–31.
[3] Adolf, G. R. (1985) Structure and effects of interferon-gamma. Oncology 42, 1–10.
[4] Carnaud, C., Lee, D., Donnars, O., Park, S. H., Beavis, A., Koezuka, Y., Bendelac, A. (1999) Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163, 4647–4650.
[5] Frucht, D. M., Fukao, T., Bogdan, C., Schindler, H., O’Shea, J. J., Koyasu, S. (2001) IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 22, 556–560.
[6] Gessani, S., Belardelli, F. (1998) IFN-gamma expression in macrophages and its possible biological significance. Cytokine Growth Factor Rev. 9,117–123.
[7] Munder, M., Mallo, M., Eichmann, K., Modolell, M. (1998) Murine
macrophages secrete interferon gamma upon combined stimulation with
interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage
activation. J. Exp. Med. 187, 2103–2108.
[8] Fukao, T., Matsuda, S., Koyasu, S. (2000) Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells.
J. Immunol. 164, 64–71.
[9] Schindler, H., Lutz, M. B., Rollinghoff, M., Bogdan, C. (2001) The
production of IFN-gamma by IL-12/IL-18-activated macrophages requires STAT4 signaling and is inhibited by IL-4. J. Immunol. 166,
3075–3082.
[10] Bach, E. A., Szabo, S. J., Dighe, A. S., Ashkenazi, A., Aguet, M., Murphy,K. M., Schreiber, R. D. (1995) Ligand-induced autoregulation of IFNgamma receptor beta chain expression in T helper cell subsets. Science 270, 1215–1218.
[11] Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., Schreiber, R. D. (1998) Demonstration of an interferon gamma dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95, 7556–7561.
[12] Greenlund, A.C., Farrar, M.A., Viviano, B.L., Schreiber, R. D. (1994) Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). EMBO J. 13, 1591–1600.
[13] Briscoe, J., Rogers, N. C., Witthuhn, B. A., Watling, D., Harpur, A.G., Wilks, A.F., Stark, G.R. , Ihle , J.N. ,Kerr,I.M. (1996) Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state. EMBO J. 15, 799–809.
[14] Igarashi, K., Garotta, G., Ozmen, L., Ziemiecki, A., Wilks, A. F., Harpur, A. G., Larner, A. C., Finbloom, D. S. (1994) Interferon-gamma induces tyrosine phosphorylation of interferon-gamma receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor. J. Biol. Chem. 269, 14333–14336.
[15] Darnell Jr., J. E., Kerr, I. M., Stark, G. R. (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415–1421.
[16] Schindler, C., Darnell Jr., J. E. (1995) Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 64,
621–651.
[17] Ramana, C.V., Chatterjee-Kishore, M., Nguyen, H., Stark, G. R. (2000) Complex roles of Stat1 in regulating gene expression. Oncogene 19, 2619–2627
[18] Paludan, S.R. (1998)Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship. Scand. J. Immunol. 48,459–468.
[19] Schroder, K., Hertzog, P. J., Ravasi, T., and Hume, D. A. (2003) Interferon-γ: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75, 163–189. doi:10.1189/jlb.0603252
[20] Davies, E. G., Isaacs, D., Levinsky, R. J. (1982) Defective immune interferon production and natural killer activity associated with poor neutrophil mobility and delayed umbilical cord separation. Clin. Exp. Immunol. 50, 454–460.
[21] Dighe, A. S., Richards, E., Old, L. J., Schreiber, R. D. (1994) Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1, 447–456.
[22] Tannenbaum, C. S., Hamilton, T. A. (2000) Immune-inflammatory mechanisms in IFNgamma-mediated anti-tumor activity. Semin. Cancer Biol. 10, 113–123.
[23] Lee, J. Y., Goldman, D., Piliero, L. M., Petri, M., Sullivan, K. E. (2001)Interferon-gamma polymorphisms in systemic lupus erythematosus. Genes Immun. 2, 254–257.
[24] Baechler, E. C., Batliwalla, F. M., Karypis, G., Gaffney, P. M., Ortmann, W. A., Espe, K. J., Shark, K. B., Grande, W. J., Hughes, K. M., Kapur, V., Gregersen, P. K., Behrens, T. W. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100, 2610–2615.
[25] Soyoz, M., Pehlivan, M., Tatar, E., Cerci, B., Coven, H. I. K., and Ayna, T. K. (2021) Consideration of IL-2, IFN-γ and IL-4 expression and methylation levels in CD4+ T cells as a predictor of rejection in kidney transplant. Transpl. Immunol. 68, 101414. doi:10.1016/j.trim.2021.101414
[26] Baik, S. H., Kang, S., Lee, W., Choi, H., Chung, S., Kim, J.-I., and Mook-Jung, I. (2019) A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer's Disease. Cell Metab. 30(3), 493–507. doi:10.1016/j.cmet.2019.06.005
Copyright © 2026 北京索萊寶科技有限公司版權(quán)所有 備案號(hào)：
技術(shù)支持：化工儀器網(wǎng) 管理登錄 sitemap.xml
當(dāng)前位置：
